6:07 PM
Oct 22, 2012
 |  BC Extra  |  Company News

Actelion seeks FDA approval of macitentan for PAH

Actelion Ltd. (SIX:ATLN) submitted an NDA to FDA for Opsumit macitentan to treat pulmonary arterial hypertension. The application...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >